V2 Receptor Antagonist; Tolvaptan
Electrolytes & Blood Pressure
;
: 50-54, 2011.
Artículo
en Inglés
| WPRIM
| ID: wpr-191398
ABSTRACT
Hyponatremia is the most common electrolyte disorder in hospitalized patients. Many studies documented that it was related to increased morbidity and mortality in patients with congestive heart failure, liver cirrhosis, and neurologic diseases. Although knowledge of hyponatremia has been cumulated, the optimal management of hyponatremia remains incompletely established in clinical practice because of the diversity of underlying disease states, and its multiple causes with differing pathophysiologic mechanisms. Since vasopressin receptor antagonists have unique aquaretic effect to selectively increase electrolytes-free water excretion, clinicians could apply a more effective method to treat hyponatremia. Tolvaptan has significant evidence that it improves serum sodium levels in patients with euvolemic or hypervolemic hyponatremia related with heart failure, cirrhosis or syndrome of inappropriate anti-diuretic hormone. Tolvaptan has acceptable safety and tolerability for long-term usage in chronic hyponatremia, and the beneficial effects on serum Na+ occurred in patients with both mild and marked hyponatremia.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Sodio
/
Benzazepinas
/
Fibrosis
/
Agua
/
Receptores de Vasopresinas
/
Insuficiencia Cardíaca
/
Hiponatremia
/
Cirrosis Hepática
Límite:
Humanos
Idioma:
Inglés
Revista:
Electrolytes & Blood Pressure
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS